Deficient leukemia inhibitory factor signaling in muscle precursor cells from patients with type 2 diabetes

Christa Broholm1, Claus Brandt, Ninna S Schultz

  • 1Centre of Inflammation and Metabolism, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. christa.broholm@gmail.com

Insights

Type 2 diabetes impairs skeletal muscle precursor cell response to leukemia-inhibitory factor (LIF), hindering muscle repair. Diabetic muscle shows increased LIF and LIF receptor but reduced LIF signaling and proliferation, suggesting a novel mechanism of muscle dysfunction.

Area of Science:

  • Muscle Biology
  • Endocrinology
  • Cell Signaling

Background:

  • Leukemia-inhibitory factor (LIF) promotes skeletal muscle precursor cell proliferation, crucial for muscle maintenance and repair.
  • Type 2 diabetes is associated with impaired muscle function, but the underlying molecular mechanisms are not fully understood.

Purpose of the Study:

  • To investigate the hypothesis that muscle precursor cells from type 2 diabetes patients exhibit a deficient response to LIF.
  • To elucidate the role of LIF signaling in skeletal muscle dysfunction in type 2 diabetes.

Main Methods:

  • Quantitative PCR (qPCR) and Western blot to measure LIF and LIF receptor (LIFR) expression in muscle biopsies and cultured myoblasts.
  • Assessment of myoblast proliferation using bromodeoxyuridine incorporation.
  • Analysis of LIF signaling pathways (STAT1, STAT3 phosphorylation) and gene expression following LIF stimulation and SOCS3 knockdown in myoblast cultures.

Main Results:

  • Diabetic muscle tissue and myoblasts showed increased LIF and LIFR protein levels.
  • LIF-induced STAT1 and STAT3 phosphorylation was impaired in diabetic myoblasts.
  • Diabetic myoblasts displayed a deficient proliferative response to LIF and reduced expression of proliferation-promoting factors (cyclin D1, JunB, c-myc).
  • Suppressor of cytokine signaling (SOCS)3 protein was upregulated in diabetic myoblasts, and its knockdown partially restored LIF-induced gene expression.

Conclusions:

  • Despite increased LIF and LIFR, LIF signaling and LIF-stimulated proliferation are impaired in skeletal muscle precursor cells from type 2 diabetes patients.
  • Upregulated SOCS3 may contribute to the impaired LIF response in diabetic myoblasts.
  • This study identifies a novel mechanism contributing to compromised muscle function in type 2 diabetes.

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...